New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication is added to previous indications: gliomas, locally advanced SCCHN, nasopharyngeal cancer and esophageal cancer.